Cargando…
阿美替尼联合贝伐珠单抗治疗晚期NSCLC伴原发EGFR T790M突变:3例病案报道及文献复习
With the development of sequencing technology, the detection rate of non-small cell lung cancer (NSCLC) with primary epidermal growth factor receptor (EGFR) T790M mutation is increasing. However, the first-line treatment for primary EGFR T790M-mutated NSCLC still lacks standard recommendations. Here...
Autores principales: | YANG, Xue, MENG, Fanlu, ZHONG, Diansheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial board of Chinese Journal of Lung Cancer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033243/ https://www.ncbi.nlm.nih.gov/pubmed/36872054 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.04 |
Ejemplares similares
-
奥希替尼联合贝伐珠单抗在获得性EGFR T790M突变晚期非小细胞肺癌的疗效分析
Publicado: (2022) -
贝伐珠单抗在晚期非小细胞肺癌一线治疗中的研究进展
Publicado: (2020) -
贝伐珠单抗在非小细胞肺癌中的应用进展
Publicado: (2017) -
贝伐珠单抗联合紫杉醇/卡铂治疗晚期非小细胞肺癌25例分析
Publicado: (2012) -
预测贝伐珠单抗抗肿瘤治疗效果的生物学标记物
Publicado: (2011)